- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04885712
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
May 22, 2023 updated by: Boryung Pharmaceutical Co., Ltd
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
378
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Those who voluntarily signed the informed consent to participate in this study.
- Adults aged 19 years or older.
- Those diagnosed with type 2 diabetes mellitus.
- Subjects taking constant doses of ≥1000mg of Metformin and 10 mg of Dapagliflozin for more than 8 weeks at Visit 1 (regardless of dosage forms (immediate-release and sustained-release) and single agent or combination drug.)
- Subjects with 7% ≤ HbA1c ≤ 10.5% at Visit 1 and Visit 2
- Subjects able to understand the study, comply with study procedures, and attend all scheduled visits.
Exclusion Criteria:
- Uncontrolled hyperglycemia at Visit 1 or Visit 2 (subjects with FPG > 270 mg/dL as a result of the test conducted by the study institution.)
- Medication compliance is <70% or >120% for each BR3003D, BR3003C, BR3003A-2, and BR3003B-2 during the Run-in period at Visit 2.
- Patients with other types of diabetes instead of type 2 diabetes (e.g., type 1 diabetes, secondary diabetes, or congenital renal glycosuria).
- Patients with uncontrolled, severe diabetic complications (e.g., proliferative diabetic retinopathy uncontrolled despite medication and severe diabetic neuropathy)
- Those who suffered from acute or chronic metabolic acidosis within 3 months as of Visit 1, including lactic acidosis and diabetic ketoacidosis.
- Those with > 40 kg/m2 of BMI measured at Visit 1.
- Those with uncontrolled hypertension at Visit 1 or Visit 2 (SBP > 180 mmHg or DBP > 110 mmHg).
- Those diagnosed with cardiovascular diseases (myocardial infarction, stroke, unstable angina, and transient ischemic attack (TIA)) or undergo revascularization within 3 months as of Visit 1
- Those with heart failure (NYHA class II~IV) or who had suffered from heart failure.
- Those who suffered from gastrointestinal diseases that may affect the absorption, distribution, metabolism, and excretion of investigational products or had underwent surgery;
- Those who underwent surgery requiring general anesthesia within 4 weeks as of Visit 1 or who are scheduled to receive such surgery within 4 weeks after the study ends
- Those with a history of malignant tumor within 5 years as of Visit 1
- Those who have a clinically significant liver disease
- Those who have a clinically significant renal disease
- Those with clinically significant hematuria detected at Visit 1 or Visit 2
- Those with chronic diseases requiring the continued use of systemic steroid or immunosuppressants (oral administration, injection, or inhalation).
- Patients with pituitary insufficiency or adrenal insufficiency.
- Those with clinically significant severe infection or trauma based on an investigator's judgement.
- Patients with AIDS.
- Patients with acute or chronic diseases that may cause histotoxic hypoxia such as respiratory failure and shock.
- Those who need treatment due to dehydration caused by persistent diarrhea and vomiting or at a risk of fluid volume depletion.
Those who have been administered with the following drugs or expected to require the continued administration during the study period:
- Those administered with systemic steroid agents (Prednisolone, >30 mg/day) within 2 weeks as of Visit 1.
- Those being administered with thyroid medications and whose dose has been modified within 6 weeks as of Visit 1 (however, dose reduction is accepted.)
- Those being administered with diuretics and whose dose has been modified within 8 weeks as of Visit 1 however, dose reduction is accepted.)
- Those who have been administered with antidiabetics other than Metformin and Dapagliflozin within 8 weeks as of Visit 1.
- Those who have been administered with obesity drugs (e.g., phentermine, phendimetrazine, diethylpropion, and mazindol) within 12 weeks as of Visit 1.
- Those who need to take prohibited concomitant medications stated here during the study period.
- Those with history of alcohol or drug abuse within 1 year as of Visit 1.
- Those who had allergic reaction to main ingredients or components of the investigational products.
- Those who had genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.
- Females who are pregnant or breastfeeding.
- Patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method
- Those who are currently participating in other ongoing clinical studies or those who have taken the investigational products from other clinical studies within 12 weeks as of Visit 1
- Those who are judged unsuitable for the study by a principal investigator or investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg + Pioglitazone 30mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg Pioglitazone 30mg placebo
|
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
|
Experimental: Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 30mg +Pioglitazone 15mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 30mg Pioglitazone 15mg placebo
|
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
|
Active Comparator: Metformin≥1000mg + Dapagliflozin 10mg + Pioglitazone 15mg Placebo+ Pioglitazone 30mg Placebo
Metformin≥1000mg Dapagliflozin 10mg Pioglitazone 15mg placebo Pioglitazone 30mg placebo
|
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
Subjects take the investigational products once a day for 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in HbA1c
Time Frame: 24th week
|
Changes in HbA1c at the 24th week after the administration of investigational products from the baseline
|
24th week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Woo-je Lee, Asan Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 28, 2021
Primary Completion (Actual)
September 19, 2022
Study Completion (Actual)
March 10, 2023
Study Registration Dates
First Submitted
May 9, 2021
First Submitted That Met QC Criteria
May 9, 2021
First Posted (Actual)
May 13, 2021
Study Record Updates
Last Update Posted (Actual)
May 24, 2023
Last Update Submitted That Met QC Criteria
May 22, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR-DPC-CT-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Johns Hopkins UniversityBeth Israel Deaconess Medical CenterActive, not recruitingHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
University of ChicagoCompleted
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityUnknown
-
University of AlbertaSherwood Park Strathcona County Primary Care Network, AlbertaCompleted
-
Brittany L SmallsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
LMC Diabetes & Endocrinology Ltd.Merck Sharp & Dohme LLC; Syreon CorporationWithdrawnType2 Diabetes
Clinical Trials on Metformin≥1000mg
-
Dong Wha Pharmaceutical Co. Ltd.Completed
-
Handok Inc.CompletedHealthy VolunteersKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Dong-A ST Co., Ltd.UnknownDiabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease | Renal DiseaseKorea, Republic of
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
GC Biopharma CorpRecruitingHealthy VolunteersKorea, Republic of
-
GC Biopharma CorpRecruitingHealthy VolunteersKorea, Republic of
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of